Non-clinical Development of a Synthetic Lung Surfactant for Treatment of NRDS

用于治疗 NRDS 的合成肺表面活性剂的非临床开发

基本信息

批准号：
10432112
负责人：
Gary Fujii
金额：
$ 103.18万
依托单位：
MOLECULAR EXPRESS, INC.
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-06-18 至 2023-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10432112
关键词：
37 weeks gestation Advanced Development Animals Applications Grants Biological Assay Bronchopulmonary Dysplasia Businesses Case Study Cause of Death Cessation of life Chemical Surfactants Child Clinical Clinical Protocols Clinical Research Clinical Trials Cyclic GMP Development Equipment FDA approved Facility Construction Guidelines Human Human Resources Incidence Infant Investigation Life Lipids Live Birth Methods Molecular Morbidity - disease rate Neonatal Respiratory Distress Nosocomial Infections Oryctolagus cuniculus Performance Pharmaceutical Preparations Pharmacologic Substance Phase Phase I Clinical Trials Phase II Clinical Trials Pregnancy Premature Birth Premature Infant Procedures Proteins Public Health Pulmonary Surfactant-Associated Protein B Pulmonary Surfactants Qualifying Quality Control Research Risk Safety Sales Schedule Secure Small Business Innovation Research Grant Source System Training Translating analytical method base cost cost effective improved infant morbidity/mortality intraventricular hemorrhage low and middle-income countries manufacturing process meetings mortality neonate peptide B peptidomimetics pre-clinical preclinical development premature preterm newborn public health relevance respiratory surfactant surfactant deficiency

项目摘要

Project Summary/Abstract Surfactant deficiency in preterm infants causes the neonatal respiratory distress syndrome (NRDS). NRDS directly causes mortality and morbidity. NRDS also increases the risk of intraventricular hemorrhage, bronchopulmonary dysplasia, and nosocomial infections. The burden of NRDS has been conservatively estimated at 1% of all live births, or 1.4 million neonates globally, with a reported case fatality for untreated NRDS of 57 to 89% in low- and middle-income countries. Although animal-derived surfactants for treating NRDS developed in the 1980s greatly decreased preterm infant morbidity and mortality, fewer than one-third of premature infants receive surfactant treatment (based on surfactant sales). Cost constraints and lack of supply are primary factors for why the remaining two-thirds are not treated. To help fill this need, Molecular Express, Inc. proposes to complete the late stage development and preclinical activities for ME-101, an investigational lung surfactant comprised of the Super Mini-B peptide, which mimics Surfactant Protein B, the protein component primarily responsible for lung surfactant activity, as well as the three-major lipids of natural human lung surfactant. ME-101 is a fully synthetic lung surfactant - i.e., it is not limited by supply as is the case with animal derived products and has significant advantages in being well-defined with consistent activity, product uniformity, and economy of manufacturing over currently marketed animal and synthetic lung surfactants. The primary Aims of this Direct-to-Phase II SBIR application are to establish a commercially viable process for manufacturing and quality control of ME-101, implement a quality management system, produce and release a cGMP lot of ME- 101, perform IND enabling activities, and organize, schedule and conduct a Pre-IND meeting with the FDA to gain final alignment on the clinical studies to demonstrate safety, tolerability, and efficacy. Successful execution of these Aims will advance the development of a synthetic lung surfactant with commercial attractiveness due to advantages over other synthetic surfactants in activity and manufacturing economy. Reduced cost to consumers can potentially translate into broadened surfactant treatment of NRDS and potentially other indications for use thus exerting a significant impact on improving global public health.

项目概要/摘要早产儿表面活性剂缺乏会导致新生儿呼吸窘迫综合征（NRDS）。 NRDS 直接导致死亡和发病。 NRDS 还会增加脑室内出血的风险，支气管肺发育不良和医院感染。 NRDS 的负担一直保守据估计，全球有 140 万新生儿因未经治疗的 NRDS 死亡，占所有活产的 1% 低收入和中等收入国家的这一比例为 57% 至 89%。尽管动物源性表面活性剂可用于治疗 NRDS 20世纪80年代开发的技术大大降低了早产儿的发病率和死亡率，不到三分之一早产儿接受表面活性剂治疗（基于表面活性剂销售情况）。成本限制和供应不足是其余三分之二未得到治疗的主要原因。为了帮助满足这一需求，分子快递， Inc.提议完成ME-101的后期开发和临床前活动，ME-101是一种研究性药物肺表面活性剂由 Super Mini-B 肽组成，模拟表面活性剂蛋白 B（蛋白质成分）主要负责肺表面活性物质活性，以及天然人肺的三大脂质表面活性剂。 ME-101 是一种全合成肺表面活性剂 - 即，它不像动物那样受到供应限制衍生产品，并具有明确的显着优势，具有一致的活性、产品均匀性、与目前市场上销售的动物和合成肺表面活性剂相比，其制造经济性和经济性。主要目标这个直接进入第二阶段 SBIR 应用的目的是建立一个商业上可行的制造和 ME-101的质量控制，实施质量管理体系，生产并发布cGMP批次的ME- 101，执行 IND 授权活动，并与 FDA 组织、安排和举行 IND 前会议，获得临床研究的最终一致性，以证明安全性、耐受性和有效性。执行成功这些目标将促进具有商业吸引力的合成肺表面活性剂的开发，因为在活性和制造经济性方面优于其他合成表面活性剂。降低消费者成本可以潜在地转化为扩大 NRDS 的表面活性剂治疗以及潜在的其他使用适应症从而对改善全球公共卫生产生重大影响。